BridgeBio Pharma
BBIO
66.50
-0.46
-0.69%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
66.50
-0.46
-0.69%
Live - 5344 symbols - heartbeat 66s ago
· 2026-10-08 05:32
Pre-market
66.30
-0.30%
After-hours
65.99
-0.77%
Overnight
66.50
0.00%
- Market cap
- 13.00B
- P/E (TTM)i
- -18.68
- P/Bi
- -5.17
- EPSi
- -3.78
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on BBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.71, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +126.26% YoY
Margins
- Gross margin
- 95.82%
- Operating margin
- -100.00%
- Net margin
- -144.39%
Key ratios & quality
- Enterprise valuei
- 14.27B
- Altman Z-Scorei
- -3.71
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 40.56M | 8.25M | 69.72M | 77.65M | 9.30M | 221.90M | 502.08M |
| Gross profit | 0 | 38.06M | 8.25M | 66.60M | 74.21M | 6.86M | 218.02M | 481.11M |
| Selling & admin expenses | 43.59M | 94.35M | 145.68M | 192.21M | 143.19M | 150.59M | 288.93M | 531.23M |
| Research & development | 140.07M | 209.95M | 337.05M | 451.02M | 399.46M | 455.71M | 506.46M | 451.95M |
| Operating profit | -183.66M | -266.24M | -474.48M | -576.63M | -468.44M | -599.44M | -577.37M | -502.06M |
| Pretax profit | -169.45M | -288.59M | -505.49M | -586.45M | -484.65M | -653.25M | -542.19M | -732.50M |
| Tax | -- | -- | -- | -- | 0 | 0 | 1.15M | 435.00K |
| Net profit | -169.45M | -288.59M | -505.49M | -586.45M | -484.65M | -653.25M | -543.35M | -732.94M |
| Basic EPS | -1 | -2 | -4 | -4 | -3 | -4 | -3 | -4 |
| Diluted EPS | -1.42 | -2.48 | -3.80 | -3.90 | -3.26 | -3.95 | -2.88 | -3.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 116.63M | 110.57M | 120.70M | 154.18M | 194.52M | 243.68M |
| Gross profit | 113.99M | 106.91M | 114.14M | 146.07M | 184.58M | 228.63M |
| Selling & admin expenses | 106.37M | 129.15M | 137.62M | 158.09M | 163.90M | 186.26M |
| Research & development | 111.43M | 111.23M | 112.87M | 116.42M | 126.64M | 149.45M |
| Operating profit | -103.80M | -133.47M | -136.36M | -128.43M | -105.96M | -107.08M |
| Pretax profit | -169.61M | -181.66M | -186.48M | -194.76M | -166.56M | -155.89M |
| Tax | -- | 2.10M | -1.55M | -120.00K | -- | 0 |
| Net profit | -169.61M | -183.76M | -184.94M | -194.64M | -166.56M | -155.89M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.88 | -0.95 | -0.95 | -1.00 | -0.84 | -0.78 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 445.22M | 568.62M | 642.82M | 888.86M | 548.85M | 477.59M | 720.69M | 797.75M |
| Cash & ST investments | 436.09M | 545.99M | 607.09M | 836.66M | 471.92M | 434.88M | 681.10M | 587.48M |
| Inventory | -- | -- | -- | -- | -- | -- | 0 | 26.75M |
| Total assets | 464.94M | 631.68M | 703.59M | 1.01B | 623.04M | 546.38M | 919.34M | 936.03M |
| Total current liabilities | 32.58M | 60.39M | 95.65M | 135.07M | 121.43M | 143.84M | 154.40M | 287.97M |
| Short-term debt | -- | -- | 5.25M | 4.94M | 3.68M | 4.13M | 4.51M | 6.19M |
| Long-term debt | 54.51M | 91.79M | 475.86M | 1.70B | 1.71B | 1.73B | 1.72B | 1.85B |
| Total liabilities | 87,579,000.00 | 155,703,000.00 | 595,702,000.00 | 1,878,371,000.00 | 1,867,960,000.00 | 1,888,915,000.00 | 2,376,950,000.00 | 3,012,606,000.00 |
| Total equity | 377.36M | 475.98M | 107.89M | -865.58M | -1.24B | -1.34B | -1.46B | -2.08B |
| Retained earnings | -179.44M | -440.03M | -888.76M | -1.44B | -1.92B | -2.56B | -3.10B | -3.82B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 695.17M | 912.28M | 839.38M | 797.75M | 1.24B | 1.09B |
| Cash & ST investments | 540.60M | 756.89M | 645.94M | 587.48M | 940.19M | 720.16M |
| Inventory | 3.95M | 18.28M | 24.53M | 26.75M | 32.98M | 52.84M |
| Total assets | 881.64M | 1.08B | 998.25M | 936.03M | 1.37B | 1.22B |
| Total current liabilities | 152.11M | 175.85M | 216.60M | 287.97M | 816.37M | 890.65M |
| Short-term debt | 5.21M | 4.78M | 5.29M | 6.19M | 551.92M | 551.27M |
| Long-term debt | 1.85B | 1.85B | 1.85B | 1.85B | 1.93B | 1.93B |
| Total liabilities | 2,520,303,000.00 | 2,858,609,000.00 | 2,920,979,000.00 | 3,012,606,000.00 | 3,639,856,000.00 | 3,723,192,000.00 |
| Total equity | -1.64B | -1.78B | -1.92B | -2.08B | -2.27B | -2.51B |
| Retained earnings | -3.26B | -3.45B | -3.63B | -3.82B | -3.99B | -4.14B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -136.64M | -253.59M | -399.71M | -497.93M | -419.49M | -527.72M | -520.73M | -445.91M |
| Depreciation & amortization | 0 | 859.00K | 1.46M | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| Free cash flow | -154.82M | -256.23M | -407.23M | -546.18M | -425.82M | -529.03M | -529.63M | -455.50M |
| Dividends paid | 0 | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 95.54M | 366.24M | -75.71M | -204.75M | 3.29M | 442.93M | 307.22M | -62.50M |
| Ending cash balance | 436.25M | 364.20M | 358.68M | 396.37M | 416.88M | 394.73M | 683.24M | 572.14M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -199.24M | -80.68M | -109.57M | -56.42M | -197.28M | -71.10M |
| Depreciation & amortization | 1.28M | 1.32M | 1.40M | 1.44M | 1.19M | 1.05M |
| Free cash flow | -200.83M | -85.78M | -112.44M | -56.45M | -197.35M | -71.54M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -50.05M | -2.00M | -3.03M | -7.43M | -86.57M | -131.77M |
| Ending cash balance | 542.74M | 751.10M | 645.10M | 572.14M | 882.02M | 680.04M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -213.19 | -192.44 | -- | -- | -- | -- | -- |
| ROA %i | -51.17 | -47.53 | -67.21 | -65.55 | -58.83 | -110.00 | -73.11 | -78.14 |
| ROIC %i | -- | -133.45 | -78.57 | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -689.89 | -5,683.51 | -774.11 | -520.57 | -6,148.15 | -199.59 | -110.39 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 13.67 | 9.42 | 6.72 | 6.58 | 4.52 | 3.32 | 4.67 | 2.77 |
| Quick ratioi | 13.39 | 9.09 | 6.35 | 6.34 | 4.03 | 3.04 | 4.44 | 2.52 |
| Debt / assetsi | 11.72 | 14.53 | 70.47 | 170.44 | 276.64 | 318.43 | 188.24 | 198.98 |
| LT debt / equityi | 17.31 | 22.47 | 847.12 | -- | -- | -- | -- | -- |
| Interest coveragei | -65.53 | -31.92 | -12.79 | -11.54 | -5.03 | -7.04 | -4.46 | -3.11 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 24.17 | 4.09 | 47.10 | 86.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -77.18 | -82.84 | -95.85 | -78.14 | -64.06 | -60.23 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -437.69 | -275.26 | -182.67 | -110.39 | -93.20 | -69.81 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.57 | 5.19 | 3.88 | 2.77 | 1.52 | 1.23 |
| Quick ratioi | 4.31 | 4.74 | 3.52 | 2.52 | 1.40 | 1.09 |
| Debt / assetsi | 210.77 | 172.04 | 186.30 | 198.98 | 181.78 | 204.86 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -4.73 | -4.89 | -4.10 | -3.11 | -2.86 | -2.42 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Identifying, advancing and commercializing transformative medicines to treat patients100.00%
Quote time 2026-10-08 05:32:13 · For reference only, not investment advice and not tailored to your situation.